Using STING activators to enhance cancer treatment
STING Activators as Therapy for Cancer
['FUNDING_OTHER'] · STINGINN, LLC · NIH-10709468
This study is looking at a new way to help your immune system fight aggressive leukemia by using a special treatment that activates a protein called STING, and it’s designed for patients whose leukemia has come back or hasn’t responded to other treatments.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | STINGINN, LLC (nih funded) |
| Locations | 1 site (MIAMI, UNITED STATES) |
| Trial ID | NIH-10709468 on ClinicalTrials.gov |
What this research studies
This research investigates how to stimulate the body's immune system to fight cancer more effectively by activating a protein called STING. The approach focuses on enhancing the generation of anti-cancer T cells through the activation of antigen-presenting cells, which play a crucial role in immune response. The study will involve a small clinical trial for patients with aggressive forms of leukemia, specifically targeting relapsed or refractory acute myeloid leukemia and adult lymphocytic leukemia. Patients will receive treatment that aims to boost their immune response against their cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults suffering from relapsed or refractory acute myeloid leukemia or adult lymphocytic leukemia.
Not a fit: Patients with cancers other than the specified leukemias or those who are not eligible for the clinical trial may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy options for patients with aggressive leukemias.
How similar studies have performed: Other research has shown promising results with similar immunotherapeutic approaches, indicating potential for success in this area.
Where this research is happening
MIAMI, UNITED STATES
- STINGINN, LLC — MIAMI, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BARBER, GLEN N — STINGINN, LLC
- Study coordinator: BARBER, GLEN N
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.